Sabby Management’s Carisma Therapeutics CARM Stock Holding History

Sabby Management’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18	Closed	-$43K	–	75
2019 Q3	$43K	Sell	18 -10	-36%	-$234	0.02%	84
2019 Q2	$70K	Buy	+28	New	+$838	0.09%	74
2019 Q1	–	Sell	-92	Closed	-$260K	–	90
2018 Q4	$260K	Buy	92 +1	+1%	+$32	0.06%	66
2018 Q3	$392K	Buy	91 +41	+82%	+$1.6K	0.05%	80
2018 Q2	$196K	Buy	+50	New	+$2.2K	0.03%	101

Other funds holding CARM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sabby Management's CARM Position: Q2 2018 in Review

Sabby Management sold out of Carisma Therapeutics (CARM) in Q2 2018, closing a stake of 61,306 shares — an estimated $2.7M sold.

Sabby Management first reported a position in CARM in Q2 2014 and held it in 7 quarters. The position peaked at $1.9M in Q2 2014. 46 funds tracked by Wall St. Rank hold CARM as of Q2 2018.

Sabby Management reported no remaining Carisma Therapeutics position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 61,306 Carisma Therapeutics shares in Q2 2018, an estimated $2.7M.
Sabby Management first reported a position in Carisma Therapeutics in Q2 2014 and held it in 7 quarters.
Sabby Management's Carisma Therapeutics position peaked at $1.9M in Q2 2014.
46 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.